In another phase II, open-label, multicentre study of T-VEC in patients with stage IIIB-IVM1c melanoma, the ORR of mutant BRAF was 10 (25%) patients, and that of wild-type BRAF was 20 (29%) patients [9]. Here, BRAF is linked to melanoma.